On June 11, Akeso announced that its self-developed IL-17A monoclonal antibody, Gumokimab (AK111, brand name Qiyoukang®), received approval from China’s National Medical Products Administration (NMPA) for the treatment of adults with moderate-to-severe plaque psoriasis. The…
On June 4, 2026, the NMPA officially announced that injectable Bemiltenase alfa (Goxblem), a Class 1 innovative biologic developed by BioJeTay, a subsidiary of Shutaishen Pharmaceutical Group, received conditional approval in China. The drug is…
China’s innovative drug industry continues to achieve major breakthroughs. According to public information released by China’s National Medical Products Administration (NMPA), May 2026 China innovative drug approvals included 5 newly approved therapies covering insomnia, myasthenia…
On May 21, Johnson & Johnson announced that its FcRn antagonist Imaavy® (nipocalimab injection) received approval from China’s National Medical Products Administration (NMPA) for use in combination with standard therapy in adolescents aged 12 years…
On May 15, 2026, AbbVie announced that its CD20×CD3 bispecific antibody — Epkinly (Epcoritamab) — has been approved by China’s National Medical Products Administration (NMPA). This marks a significant milestone in lymphoma treatment, as epcoritamab…
April 2026 marked another milestone for China innovative drug approvals April 2026, as the country witnessed a new wave of regulatory clearances across oncology, hematology, nuclear medicine, and inflammatory diseases. According to public information released…
On April 27, 2026, the National Medical Products Administration (NMPA) announced that Jiangsu Huayang Pharmaceutical’s extended-release tablets became the first generic upadacitinib approved in China after passing generic consistency evaluation. This milestone—generic upadacitinib approved in…
On April 17, China’s National Medical Products Administration (NMPA) approved belantamab mafodotin in combination with bortezomib and dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least…
On April 15, Bayer announced that its innovative targeted therapy Hyrnuo® (sevabertinib, BAY 2927088) has been officially approved by the National Medical Products Administration. ✨ This milestone marks sevabertinib approved in China for HER2-mutant NSCLC,…
On March 27, 2026, the National Medical Products Administration (NMPA) of China officially approved GSK Exdensur (depemokimab) in China for marketing. The approval covers maintenance treatment of adults and adolescents aged 12 years and older…
The ABSK061 achondroplasia orphan drug designation marks an important regulatory milestone in the development of targeted therapies for rare genetic skeletal disorders. Developed by Abbisko Therapeutics, ABSK061 is a selective FGFR2/3 inhibitor designed to target…
In February 2026, several new cancer drugs approved by global regulatory authorities marked significant progress in oncology treatment. These approvals came from organizations including China’s National Medical Products Administration (NMPA), the U.S. Food and Drug…
